At Shorla Oncology we develop and commercialize innovative oncology drugs for women’s and pediatric cancers. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population.
Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments.
Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments.
Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Location: Ireland
Employees: 11-50
Total raised: $43.3M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 30.10.2023 | Kurma Part... | kurmapartn... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.10.2023 | Series B | $35M | - |
| 03.06.2020 | Series A | $8.3M | Seroba Lif... |
Mentions in press and media 8
| Date | Title | Description |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 10.11.2023 | Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind. | October 31, 2023. Cambridge, Massachusetts and London. Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind Ltd (‘Therakind’), a UK-based speciality pharmaceutical company have entered into an agreement u... |
| 11.10.2023 | Shorla Oncology: Specialty Pharmaceutical Company Closes $35 Million | Shorla Oncology – a U.S.-Ireland specialty pharmaceutical company – recently announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba L... |
| 05.10.2023 | Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio. | Cambridge, Massachusetts, USA. 4 October 2023. Seroba’s portfolio company, Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partner... |
| 04.10.2023 | Shorla Oncology Raises $35M in Series B Funding | Shorla Oncology, a Clonmel, Ireland- and Cambridge, MA-based pharmaceutical company, raised $35M in Series B funding. The round was led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sci... |
| 07.03.2023 | Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia. | Cambridge, MA, USA. March 7, 2023. Shorla Oncology (‘Shorla’), a US-Ireland pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatme... |
| 13.04.2022 | Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors. | Cambridge, Mass., USA. 29 March 2022. Shorla Oncology (‘Shorla’), an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman. As a preeminent leader in the biotech industry, Purcell brings... |